



The Drug Utilization Review (DUR) Board Reviewed  
the Following New Drugs/Classes on  
May 7, 2019

<b>Therapeutic Class</b>	<b>Drug Name</b>	<b>DURB Recommendations</b>
<b>Antimigraine Agents, Other</b>		
	<i>Ajovy (Subcutaneous) Injection</i>	NP/PA
	<i>Emgality (Subcutaneous) Injection</i>	NP/PA
<b>HIV/AIDS</b>		
	<i>Delstrigo (Oral) Tablet</i>	NP/PA
	<i>Pifeltro (Oral) Tablet</i>	NP/PA
<b>Cytokine &amp; CAM Antagonists</b>		
	<i>Olumiant (Oral) Tablet</i>	NP/PA
	<i>Ilumya (Subcutaneous) Injection</i>	NP/PA (for coverage on the PADL)
	<i>Remicade (Intravenous) Injection</i>	NP/PA (for coverage on the PADL)
	<i>Renflexis (Intravenous) Injection</i>	P/PA (for coverage on the PADL)
<b>Thrombopoiesis Stimulating Proteins, Single</b>		
	<i>Mulpleta (Oral) Tablet</i>	P/PA
	<i>Doptelet (Oral) Tablet</i>	NP/PA
<b>Hemophilia Treatments</b>		
	<i>Advate (Intravenous) Injection</i>	P
	<i>Afstyla (Intravenous) Injection</i>	P
	<i>Jivi (Intravenous) Injection</i>	NP/PA
	<i>Koate (Intravenous) Injection</i>	NP/PA
	<i>Monoclate-P (Intravenous) Injection</i>	NP/PA
<b>Antivirals, Oral</b>		
	<i>Xofluza (Oral) Tablet</i>	NP/PA

DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization;  
PADL=Providers' Administered Drug List